The Revolving Fund as a Technical Cooperation Mechanism for Immunization Programs in the Americas: FAQs

The Revolving Fund has been key to the success of immunization programs in the Americas, enabling the Region to become the first in the world to eliminate indigenous polio and measles viruses.  This Region has also made the greatest strides toward the elimination of rubella and congenital rubella syndrome. 

The Revolving Fund has been vital to ensuring high coverage vaccination services in the Americas and contributing to this Region’s leadership in the introduction of new vaccines.  

Through a multidisciplinary professional team in the areas of immunization, procurement, vaccine quality control, finance, and legal affairs, the Revolving Fund manages the planning and consolidation of demand, negotiations with producers, placement of purchase orders, coordination with suppliers and  monitoring of shipments, as well as the financial aspects involving paying suppliers and billing countries. It does so in accordance with its Operating Procedures.

The Revolving Fund has been a critical factor in making the Region of the Americas a global role model for the success of immunization programs and for the Region’s successful introduction of new vaccines. For this reason, promoting the Revolving Fund’s achievements and protecting its well-being is in everyone’s interest.

This document shares some frequently asked questions and answers (FAQs) to provide a greater understanding of the Revolving Fund’s significance to the Region.